Price movement over the last 24 hours
AdaptHealth Corp vs Smith & Nephew plc — how do they compare? AdaptHealth Corp trades at $10.04 (market cap $1.38B), while Smith & Nephew plc trades at $30.02 (market cap $12.73B). The key difference: Smith & Nephew plc is far larger — about 9.2× AdaptHealth Corp's market cap, and Smith & Nephew plc pays a 2.57% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | SNN | |
|---|---|---|
Market Cap | $1.38B | $12.73B |
Sector | Health | Health |
52-Week High | $13.38 | $38.70 |
52-Week Low | $8.68 | $28.73 |
Enterprise Value | $3.33B | $15.50B |
Dividend Yield | — | 2.57% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →